Takeda’s multiyear “efficiency program” is in full swing.
The Japanese pharma is set to let go a total of 641 workers in Massachusetts: 495 in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Toronto, Ontario–(Newsfile Corp. – October 4, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
Research explores the advancements, challenges, and economic implications of gene therapy for various diseases, including inherited blood disorders, malignancies treated with CAR-T cells, and diseases